SAM
NAMS icon

SEB Asset Management’s NewAmsterdam Pharma NAMS Stock Holding History

SEB Asset Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.24M Hold
272,654
– – 0.03% 352
2026
Q1 		$8.73M Buy
+272,654
New +$8.88M 0.04% 339

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

SEB Asset Management's NAMS Position: Q2 2026 in Review

SEB Asset Management held its NewAmsterdam Pharma (NAMS) position steady in Q2 2026 at 272,654 shares worth $9.24M. The position accounts for 0.03% of the portfolio, ranked #352.

SEB Asset Management first reported a position in NAMS in Q1 2026 and has held it in 2 quarters since. 178 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • SEB Asset Management held 272,654 shares of NewAmsterdam Pharma worth $9.24M as of Q2 2026.
  • SEB Asset Management left its NewAmsterdam Pharma share count unchanged in Q2 2026.
  • NewAmsterdam Pharma made up 0.03% of SEB Asset Management's portfolio in Q2 2026, its #352 holding.
  • SEB Asset Management first reported a position in NewAmsterdam Pharma in Q1 2026 and has held it in 2 quarters since.
  • 178 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.